1. Home
  2. APAM vs EWTX Comparison

APAM vs EWTX Comparison

Compare APAM & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artisan Partners Asset Management Inc.

APAM

Artisan Partners Asset Management Inc.

HOLD

Current Price

$41.08

Market Cap

2.9B

Sector

Finance

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$24.45

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APAM
EWTX
Founded
1994
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.5B
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
APAM
EWTX
Price
$41.08
$24.45
Analyst Decision
Buy
Buy
Analyst Count
4
8
Target Price
$47.00
$34.13
AVG Volume (30 Days)
507.5K
1.8M
Earning Date
02-03-2026
11-06-2025
Dividend Yield
8.71%
N/A
EPS Growth
2.95
N/A
EPS
3.71
N/A
Revenue
$1,158,234,000.00
N/A
Revenue This Year
$8.38
N/A
Revenue Next Year
$6.56
N/A
P/E Ratio
$11.25
N/A
Revenue Growth
8.88
N/A
52 Week Low
$32.75
$10.60
52 Week High
$48.50
$30.48

Technical Indicators

Market Signals
Indicator
APAM
EWTX
Relative Strength Index (RSI) 40.79 54.03
Support Level $41.50 $19.76
Resistance Level $42.04 $27.40
Average True Range (ATR) 0.69 2.31
MACD 0.05 0.02
Stochastic Oscillator 47.79 62.57

Price Performance

Historical Comparison
APAM
EWTX

About APAM Artisan Partners Asset Management Inc.

Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. In addition to its equity strategies, customers may invest in a fixed-income strategy. Strategies are often distributed to customers ranging from retail investors to institutional investors through specialized channels.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: